A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
Menon T, Lee S, Gong X, Wong S, Le G, Kwan A, Teopiz K, Ho R, Cao B, Rhee T, Jing Zheng Y, Valentino K, Lin K, Vinberg M, Lo H, McIntyre R. A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain. CNS Spectrums 2024, 1-7. PMID: 39582175, DOI: 10.1017/s1092852924000531.Peer-Reviewed Original ResearchPsychiatric medicationsEffects of GLP-1RAsReceptor agonistsEfficacy of GLP-1 receptor agonistsRandomized controlled trialsGLP-1RAsModerate weight changeMitigate weight gainPsychiatric populationsPsychotropic drugsCognitive processesWeight gainClinically meaningful effectGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsSystematic reviewPreliminary evidenceGlucose-lowering agentsLong-term safetyWeight changeMeaningful effectEfficacy profilePersonsAbnormal weightA systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders
Au H, Zheng Y, Le G, Wong S, Phan L, Teopiz K, Kwan A, Rhee T, Rosenblat J, Ho R, McIntyre R. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders. Journal Of Affective Disorders 2024, 370: 321-327. PMID: 39515485, DOI: 10.1016/j.jad.2024.11.019.Peer-Reviewed Original ResearchDorsal default mode networkFunctional connectivityMental disordersAssociated with decreased functional connectivityAssociated with increased functional connectivityRight frontal-parietal networkLateral orbitofrontal cortexFrontal-parietal networkDefault mode networkIncreased functional connectivityBrain functional connectivityBrain functional activityGlucagon-like peptide-1Orbitofrontal cortexPsychopathological domainsSalience networkVisuospatial networkMode networkParietal networkPsychiatric disordersBrain circuitsNeural circuitsGLP-1RAsGlucagon-like peptide-1 receptor activationReceptor agonistsGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)
McIntyre R, Mansur R, Rosenblat J, Rhee T, Cao B, Teopiz K, Wong S, Le G, Ho R, Kwan A. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®). Journal Of Affective Disorders 2024, 369: 922-927. PMID: 39433133, DOI: 10.1016/j.jad.2024.10.062.Peer-Reviewed Original ResearchGLP-1 RAsReporting Odds RatioFood and Drug AdministrationFDA Adverse Event Reporting SystemGLP-1European Medicines AgencyMeasures of suicidalityWorld Health OrganizationGlucagon-like peptide-1 receptor agonistsGlucagon-like peptide 1 receptor agonistsWorld Health Organization pharmacovigilance databasePeptide-1 receptor agonistsPeptide 1 receptor agonistsUnited States Food and Drug AdministrationRA exposureStates Food and Drug AdministrationSuicidal behaviorSuicidal ideationAdverse Event Reporting SystemSuicideReceptor agonistsEvent Reporting SystemSemaglutideOdds ratioPharmacovigilance database